Latest Insights - page 5 | BiopharmaTrend

Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery

Precision medicine has transformed the way we treat cancer, making it possible to match therapies to the molecular profile of each patient and revolutionize treatment approaches, leading to better outcomes. …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››

Breakout Ventures Raises $114M for Neuroscience and AI-driven Startups

Investment firm Breakout Ventures has raised a $114 million venture fund aimed at early-stage startups working in neuroscience and developing artificial intelligence technologies for biomedical research and neuroscience.

Continue ›››

DeepMind & MIT Alumni Raise $13.5M to Build «Generative Knowledge Discovery» AI

Palo Alto- and Cambridge-based Unreasonable Labs has emerged from stealth with $13.5 million in funding to develop an AI platform designed for “generative knowledge discovery”. It is designed to go …

Continue ›››

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking. Between 2015 and mid-2025, EU biotech startups attracted €25B …

Continue ›››

Open Radiology AI Model Released for CT & MRI Analysis

Radiology AI company Raidium has released Curia-2, an open source foundation model intended to serve as a shared technical framework for analyzing medical imaging data across radiology workflows. The model …

Continue ›››

Ex-Neuralink Founder Raises $290M to Restore Vision With a Rice Grain-Sized Retinal Implant

Alameda-based Science Corporation has raised $230 million in Series C financing from investors including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital to support commercialization of its …

Continue ›››

Liquid AI and Insilico Release Lightweight On-Premise AI Model for Drug Discovery

Liquid AI and Insilico Medicine have released LFM2-2.6B-MMAI, a general small AI foundation model trained into a system intended to support multiple stages of drug discovery while allowing companies to …

Continue ›››

FDA Clears AI That Flags Early Stroke Damage on Routine Brain CT Scans

CT Brain, an AI system developed by Harrison.ai, has received FDA 510(k) clearance to automatically flag signs of acute brain infarction on standard non-contrast CT scans. During a stroke, brain …

Continue ›››

Evo 2, Open-Source AI Model for Generative Genomics, Validated and Published in Nature

Evo 2, a large open-source genomic foundation model designed to analyze and generate DNA sequences has been reported in Nature with experimental validation. The work demonstrates that AI-generated DNA sequences …

Continue ›››

Tempus and Merck Deepen AI Collaboration to Study Cancer Biomarkers

Tempus AI (NASDAQ: TEM) and Merck have signed an expanded multi-year collaboration to apply AI to large multimodal clinical datasets for biomarker discovery and oncology research. Through the agreement, Merck …

Continue ›››

Japanese Pharma Ono Taps Congruence's AI for Small Molecule Discovery

Osaka-based Ono Pharmaceutical has broadened its existing partnership with Montreal-based Congruence Therapeutics to include small molecule discovery programs in neurology and immunology. Financial terms were not disclosed.

Continue ›››